Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107982 | 0.74 | KDM4E (0.36) | HIF1AEPAS1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13004730 | 0.69 | ERCC5 (0.35) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3386971 | 0.68 | KDM4E (0.54) | KDM4EALDH1A1MAPTGAAL3MBTL1 | |
| SCHEMBL10107977 | 0.67 | NPBWR1 (0.43) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL1884067 | 0.65 | KDM4E (0.57) | KDM4EALDH1A1MAPTGAAL3MBTL1 | |
| SCHEMBL10102653 | 0.64 | CTSK (0.40) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL14617053 | 0.63 | MAPT (0.57) | KDM4EALDH1A1SMN1; SMN2MAPTGAA | |
| SCHEMBL9862193 | 0.63 | ALDH1A1 (0.55) | PDE5AHIF1AEPAS1KDM4EALDH1A1 | |
| SCHEMBL10102670 | 0.62 | PSMB5 (0.47) | KDM4EALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL10102628 | 0.62 | DHODH (0.46) | KDM4EALDH1A1SMN1; SMN2GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1891011-B1 | TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 | MERCK PATENT GMBH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | PDE5A 2811/4885HIF1A 4840/4885EPAS1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.